Evaluation of propofol infusion syndrome in pediatric intensive care

American Journal of Health-System Pharmacy

Volumn 60, Issue 19, 2003, Pages 2007-2014

  Okamoto, Mark P ^a   Kawaguchi, Debra L ^b   Amin, Alpesh N ^c  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b Department of Drug Information Services ^*

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROPOFOL; INTRAVENOUS ANESTHETIC AGENT;

ANESTHESIA INDUCTION; CHILD CARE; CLINICAL PRACTICE; DRUG DISTRIBUTION; DRUG INFORMATION; HUMAN; INTENSIVE CARE; METABOLIC ACIDOSIS; MORTALITY; PHARMACIST; PRIORITY JOURNAL; PROPOFOL INFUSION SYNDROME; REVIEW; RHABDOMYOLYSIS; SCIENTIFIC LITERATURE; SEDATION; SHOCK; SYNDROME; CHILD; INTRAVENOUS DRUG ADMINISTRATION; PEDIATRICS;

ANESTHETICS, INTRAVENOUS; CHILD; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS, PEDIATRIC; PEDIATRICS; PROPOFOL;

EID: 1542649409     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.19.2007     Document Type: Review

References (48)

1. Ronan K, Gallagher TJ, George B et al. Comparison of propofol and midazolam for sedation in the intensive care unit (ICU). Crit Care Med. 1992; 20(suppl): S36.
2. Diprivan (propofol) product monograph. Wilmington, DE: AstraZeneca Pharmaceutical; 1998.
3. Morton NS, Wee M, Christie G et al. Propofol for induction of anaesthesia in children. Anaesthesia. 1988; 43:350-5.
4. Aun CS, Sung RY, O'Meara ME et al. Cardiovascular effects of iv induction in children: comparison between propofol and thiopentone. Br J Anaesth. 1993; 70:647-53.
5. Manschot HJ, Meursing AE, Axt P et al. Propofol requirements for induction of anesthesia in children of different age groups. Anesth Analg. 1992; 75:876-9.
6. Westrin P. The induction dose of propofol in infants 1-6 months of age and in children 10-16 years of age. Anesthesiology. 1991; 74:455-8.
7. Short SM, Aun CS. Haemodynamic effects of propofol in children. Anaesthesia. 1991; 46:783-5.
8. Valtonen M, Iisalo E, Kanto J et al. Comparison between propofol and thiopentone for induction of anaesthesia in children. Anaesthesia. 1988; 43:696-9.
9. Valtonen M, Iisalo E, Kanto J et al. Propofol as an induction agent in children: pain on injection and pharmacokinetics. Acta Anaesth Scand. 1989; 33:152-5.
10. Mirakhur RK. Induction characteristics of propofol in children: comparison with thiopentone. Anaesthesia. 1988; 43:593-8.
11. Center for Drug Evaluation and Research (Anesthetic and Life Support Drugs Committee). ICI's Diprivan (propofol) anesthetic has no link to pediatric deaths in ICUs. FDC Rep. 1992; 54:14.
12. AstraZeneca Pharmaceuticals. Dear health care provider letter, www.fda.gov/medwatch/safety/2001/diprivan_ deardoc.pdf(2003 Jul 24).
13. Parke TJ, Stevens JE, Rice AS et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ. 1992; 305:613-6.
14. Cook S. Propofol infusion in children. BMJ. 1992; 305:952. Letter.
15. Barclay K, Williams AJ, Major E. Propofol infusion in children. BMJ. 1992; 305:953. Letter.
16. Bodd E, Endresen L. Use of propofol (Diprivan) for children. Tidsskr Nor Laegeforen. 1992; 112:1636-7.
17. Strickland RA, Murray MJ. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med. 1995; 23:405-9.
18. Reed MD, Blumer JL Propofol bashing: the time to stop is now! Crit Care Med. 1996; 24:175-6. Letter.
19. Pepperman ML, Macrae D. A comparison of propofol and other sedative use in paediatric intensive care in the United Kingdom. Paediatr Anaesth. 1997; 7:143-53.
20. Bray RJ. Fatal myocardial failure associated with propofol infusion in a child. Anaesthesia. 1995; 50:94. Letter.
21. Plotz FB, Waalkens JH, Verkade HJ et al. Fatal side-effects of continuous propofol infusion in children may be related to malignant hyperthermia. Anaesth Intensive Care. 1996; 24:724. Letter.
22. Neff SP, Futter ME, Anderson BJ. Fatal outcome after propofol sedation in children. Anaesth Intensive Care. 1997; 25:581-3. Letter.
23. Pollock AN, McKenzie AJ, Hodges M et al. Propofol and malignant hyperthermia susceptibility. Anaesth Intensive Care. 1997; 25:583-5.
24. Kolb MS, Horne MD, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology. 1982; 56:254-62.
25. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970; 17:293-315.
26. McKenzie AJ, Couchman KG, Pollock AN. Propofol is a "safe" anaesthetic agent in malignant hyperthermia susceptible patients. Anaesth Intensive Care. 1992; 20:165-8.
27. Cray SH, Robinson BH, Cox PN. Lactic acidemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med. 1998; 26:2087-92.
28. Bray RJ. Heart block following propofol in a child. Paediatr Anaesth. 1998; 8:491-9.
29. Susla GM. Propofol toxicity in critically ill pediatric patients: show us the proof. Crit Care Med. 1998; 26:1959-60. Editorial.
30. Markowitz BP, Feuer P, Cox P. Rare events often happen infrequently: propofol complications revisited. Crit Care Med. 2000; 28:2178-9. Letter.
31. Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology. 1998; 50:301-3.
32. Cannon ML, Glazier SS, Bauman LA. Metabolic acidosis, rhabdomyolysis and cardiovascular collapse after prolonged propofol infusion. J Neurosurg. 2001; 95:1053-6.
33. Bray R. Propofol infusion in children. Crit Care Med. 2000; 28:2177-8. Letter.
34. Sochala C, Deenen D, Ville A et al. Heart block following propofol in a child. Paediatr Anaesth. 1999; 9:349-51.
35. Bray RJ. Heart block following propofol in a child. Paediatr Anesth. 2000; 10:226. Letter.
36. Cremer OL, Moons KG, Bouman EA et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001; 357:117-8. Letter.
37. Kelly DF. Propofol-infusion syndrome. J Neurosurg. 2001; 95:925-6. Editorial.
38. Badr AE, Mychaskiw G 2nd, Eichhorn JH. Metabolic acidosis associated with a new formulation of propofol. Anesthesiology. 2001; 94:536-8.
39. Friedman JA, Manno E, Fulgham JR. Propofol. J Nenrosurg. 2002; 96:1161-2. Letter.
40. Perrier ND, Baerga-Varela Y, Murray MJ. Death related to propofol use in an adult patient. Crit Care Med. 2000; 28:3071-4.
41. Martin PH, Murthy BV, Petros AJ. Metabolic, biochemical and haemodynamic effects of infusion of propofol for long-term sedation of children undergoing intensive care. Br J Anaesth. 1997; 79:276-9.
42. Hatch DJ. Propofol-infusion syndrome in children. Lancet. 1999; 353:1117-8.
43. Bray RJ. Propofol-infusion syndrome in children. Lancet. 1999; 353:2074-5. Letter.
44. Murdoch SD, Cohen AT. Propofol-infusion syndrome in children. Lancet. 1999; 353:2074-5. Letter.
45. Reed MD, Yamashita TS, Marx CM et al. A pharmacokinetically based propofol dosing strategy for sedation of the critically ill, mechanically ventilated pediatric patient. Crit Care Med. 1996; 24:1473-81.
46. Hertzog JH, Dalton HJ, Anderson BD et al. Prospective evaluation of propofol anesthesia in the pediatric intensive care unit for elective oncology procedures in ambulatory and hospitalized children. Pediatrics. 2000; 106:742-7.
47. Arduino MJ, Bland LA, McAllister SK et al. Microbial growth and endotoxin production in the intravenous anesthetic propofol. Infect Control Hosp Epidemiol. 1991; 12:535-9.
48. Abrahams JM, Reiter GT, Ackner MA et al. Propofol. J Neurosurg. 2002; 96:1160-1. Letter.